scholarly journals In silico Analysis of Human Telomerase Reverse Transcriptase (hTERT) Gene: Identification of a Distant Homolog of Melanoma Antigen Family Gene (MAGE)

2009 ◽  
Vol 7 ◽  
pp. CIN.S3392
Author(s):  
Ruhul Amin ◽  
Jesmin ◽  
Hasan Jamil ◽  
M. Anwar Hossain
Keyword(s):  
In Silico Analysis ◽  
Gene Identification ◽  
Telomerase Reverse Transcriptase ◽  
Human Telomerase Reverse Transcriptase ◽  
Melanoma Antigen ◽  
Htert Gene ◽  
Family Gene ◽  
Human Telomerase ◽  
Distant Homolog ◽  
Silico Analysis

Gold Nanoprobe-Based Detection of Human Telomerase Reverse Transcriptase (hTERT) Gene Expression

2015 ◽  
Vol 14 (4) ◽  
pp. 485-490 ◽  
Author(s):  
Mohammad Pourhassan-Moghaddam ◽  
Nosratollah Zarghami ◽  
Afshin Mohsenifar ◽  
Mohammad Rahmati-Yamchi ◽  
Hadis Daraee ◽  
...  
Keyword(s):  
Gene Expression ◽  
Reverse Transcriptase ◽  
Telomerase Reverse Transcriptase ◽  
Human Telomerase Reverse Transcriptase ◽  
Htert Gene ◽  
Human Telomerase ◽  
Gold Nanoprobe

scholarly journals siRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells

2015 ◽  
Vol 35 (2) ◽  
Author(s):  
Hua Li ◽  
Jiwen He ◽  
Huimin Yi ◽  
Guoan Xiang ◽  
Kaiyun Chen ◽  
...  
Keyword(s):  
Hepatoma Cells ◽  
Cell Penetrating Peptides ◽  
Matrix Metalloproteinase 2 ◽  
Cell Penetrating Peptide ◽  
G1 Arrest ◽  
Telomerase Reverse Transcriptase ◽  
Human Telomerase Reverse Transcriptase ◽  
Htert Gene ◽  
Cell Penetrating ◽  
Human Telomerase

In the present study, we delivered human telomerase reverse transcriptase (hTERT) siRNA into SMMC-7721 hepatoma cells using a matrix metalloproteinase-2 (MMP2)-activatable cell-penetrating peptide (aCPP). The siRNA subsequently induced down-regulation of the hTERT gene and G1-arrest, implicating the utility of this delivery system in cancer therapy.

scholarly journals The Expression of Human Telomerase Reverse Transcriptase Gene and Its Activity in Patients with B-Cell Chronic Lymphocytic Leukemia and Its Impact on Clinical Staging

2018 ◽  
Vol 10 (5) ◽  
pp. 167
Author(s):  
Ali Aljabban ◽  
Jaffar Alalsaidissa
Keyword(s):  
Gene Expression ◽  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Clinical Staging ◽  
Telomerase Reverse Transcriptase ◽  
Htert Expression ◽  
Human Telomerase Reverse Transcriptase ◽  
Htert Gene ◽  
Human Telomerase ◽  
Cell Chronic Lymphocytic Leukemia

BACKGROUND: The B-Cell chronic lymphocytic leukemia is a commonest leukemia in elderly individuals characterized by progressive accumulation of mature lymphocyte in bone marrow and peripheral blood that tend to be immortal. The identification of human telomerase reverse transcriptase (hTERT) has been correlated with disease aggressiveness in malignancies. The previous researchers showed that the hTERT expression could serve as a molecular prognostic marker for B-CLL patients. However, due to the disease differences in prevalence and aggressiveness between the western and eastern countries, there is still a need to see the correlation of hTERT in B-CLL patients of the eastern world.AIM: To test the quantitative assessment of hTERT gene expression in B-CLL patients and its prognostic value in correlation with clinical staging of disease in Iraqi patients.PATIENTS & METHODS: we used the TRAP assay to assess the hTERT gene expression in mononuclear blood cells from 43 B-CLL patients.RESULTS: The hTERT gene expression was detected in 79.1% of B-CLL patients and no positive expression in control group (P=0.001). The hTERT gene expression tends to be significantly higher in advanced B-CLL stage (P=0.0001). Also, the expression was higher among elderly patients, patients with lower hematological parameters, patients with splenomegaly or hepatomegaly, patients with a history of hypertension or diabetes mellitus, and patients with high immunophenotype score. CONCLUSION: Our research suggests that the hTERT expression could serve as a prognostic marker for Iraqi patients with B-CLL as well as western countries.

scholarly journals The Expression of Human Telomerase Reverse Transcriptase in Adult Acute Myeloid Leukemia and Its Correlation With Various Clinico-Pathological Parameters

2019 ◽  
Vol 11 (4) ◽  
pp. 25
Author(s):  
Farah AlJobori ◽  
Abdulkareem Mohammad Jaafar
Keyword(s):  
Gene Expression ◽  
Bone Marrow ◽  
Myeloid Leukemia ◽  
Telomerase Activity ◽  
Telomerase Reverse Transcriptase ◽  
Human Telomerase Reverse Transcriptase ◽  
Htert Gene ◽  
Human Telomerase ◽  
Hematological Remission ◽  
Acute Myeloid

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood, AML accounts for 80% of acute leukemia in adults, its incidence increase with age. AML can be a fatal disease so research to predict prognosis is important. Telomerase (TA) is an enzyme that stabilizes the telomere length and makes the cell immortal. It is present in some of the normal cells, fetal cells, adult germ cells, and presents in 85% of tumors in humans, it has been shown that TA can be used as a prognostic marker in some solid and hematological neoplasms. Telomere length is a factor that predicts telomere function. AIM: We test the quantitative amount of human telomerase reverse transcriptase (hTERT) gene expression in AML (diagnosed according to FAB) adult and its correlation with various clinic-pathological parameters. PATIENTS & METHODS: We used the TRAP assay to assess the hTERT gene expression in mononuclear blood cells from 40 newly diagnosed AML patients, 25 AML patients after completing their course of treatment, and 15 control health subjects. RESULTS: The mean value of hTERT in AML and control groups were [1.59 ± 1.27 anm and 0.035 ± 0.046 anm respectively], and this difference was significantly higher in patients than in control group (p = 0.0001). The telomerase activity was positive in 27 (67.5%) AML patients, while 13 (32.5%) AML patients were negative for telomerase activity. Twenty-five patients after induction chemotherapy were followed up by bone marrow and peripheral blood examination to determine the patient’s response to therapy. Complete hematological remission was achieved in 12 (48.0%) patients and incomplete hematological remission in 13 (52.0%) patients (14%). The hTERT level was significantly higher in patients before induction chemotherapy than after completion of the induction course (p = 0.0001). The hTERT level at diagnosis in patients who did not achieve complete hematological remission was significantly higher than that in patients who achieved complete hematological remission (p = = 0.026). The hTERT level after induction therapy was significantly higher in patients who did not achieve complete hematological remission than in patients who achieved complete hematological remission (p = 0.003). CONCLUSION: Our research suggests that the hTERT expression could serve as a prognostic marker for AML patients. 

Sign in / Sign up

Export Citation Format

Share Document